Guid­ance bo­nan­za: FDA, EMA, MHRA, Health Cana­da and PIC/S of­fer new ad­vice on a range of phar­ma is­sues

From da­ta man­age­ment to eval­u­at­ing new drugs for CNS metas­tases, a bevy of drug reg­u­la­tors of­fered up new guid­ance doc­u­ments over the past week.

Like most guid­ance from drug reg­u­la­tors, the in­for­ma­tion con­tained with­in the doc­u­ments re­in­forces much of what’s al­ready known for those work­ing in these ar­eas. But the guid­ance al­so of­fers a win­dow in­to what each of these agen­cies con­sid­ers to be per­ti­nent to this mo­ment, in ad­di­tion to all of the Covid-19-re­lat­ed work that they’re deal­ing with.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER